品牌现货直购
供应商:我要出现这里





查看所有供应商和价格请点击:

88899-55-2生产厂家

88899-55-2价格

88899-55-2

88899-55-2结构式
88899-55-2结构式

化源商城直购

中文名 巴佛洛霉素A1
英文名 bafilomycin A1
中文别名 维生素 D2
英文别名 (5R)-2,4-Dideoxy-1-C-{(2S,3R,4S)-3-hydroxy-4-[(2R,3S,4E,6E,9S,10S,11R,12E,14Z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl}-5-isopropyl-4-methyl-α-D-threo-pentopyranose
α-D-threo-Pentopyranose, 2,4-dideoxy-1-C-[(1S,2R,3S)-2-hydroxy-3-[(2R,3S,4E,6E,9S,10S,11R,12E,14Z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-1-methylbutyl]-4-methyl-5-C-(1-methylethyl)-, (5R)-
21-O-de(3-carboxy-1-oxo-2-propenyl)-2-demethyl-2-methoxy-24-methyl-hygrolidin
bafilomycin A
MFCD06795130
Oxacyclohexadeca-3,5,11,13-tetraen-2-one, 8-hydroxy-16-[(1S,2R,3S)-2-hydroxy-1-methyl-3-[(2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5-methyl-6-(1-methylethyl)-2H-pyran-2-yl]butyl]-3,15-dimethoxy-5,7,9,11-
α-D-threo-Pentopyranose, 2,4-dideoxy-1-C-[(1S,2R,3S)-2-hydroxy-3-[(3S,4Z,6Z,9S,10S,11R,12Z,14E)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-1-met hylbutyl]-4-methyl-5-C-(1-methylethyl)-, (5R)-
(5R)-2,4-Dideoxy-1-C-{(2S,3R,4S)-3-hydroxy-4-[(2R,3S,4E,6E,9S,10S,11R,12E,14Z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-2-pentanyl}-5-isopropyl-4- ;methyl-α-D-threo-pentopyranose
BafilomycinA1fromStreptomycesgriseus
(5R)-2,4-Dideoxy-1-C-{(2S,3R,4S)-3-hydroxy-4-[(3S,4Z,6Z,9S,10S,11R,12Z,14E)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-2-pentanyl}-5-isopropyl-4-met ;hyl-α-D-threo-pentopyranose
BAFILOMYCIN A1
bafilomycin
tetramethyl-, (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-
(3Z,5E,7R,8S,9S,11E,13E,15S,16R)-8-Hydroxy-16-[(1S,2R,3S)-2-hydroxy-1-Methyl-3-[(2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5-Methyl-6-(1-Methylethyl)-2H-pyran-2-yl]butyl]-3,15-diMethoxy-5,7,9,11-tetraMethyloxacyclohexadeca-3,5,11,13-tetraen-2-o
(3Z,5E,7R,8S,9S,11E,13E,15S,16R)-8-Hydroxy-16-((1S,2R,3S)-2-hydroxy-1-methyl-3-((2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5
Bafilomycin A1 from Streptomycesgriseus,10 ug
α-D-threo-Pentopyranose, 2,4-dideoxy-1-C-[(1S,2R,3S)-2-hydroxy-3-[(2R,3S,4E,6E,9S,10S,11R,12E,14Z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-1- methylbutyl]-4-methyl-5-C-(1-methylethyl)-, (5R)-
描述 Bafilomycin A1,一种从链霉菌属物种中分离的大环内酯类抗生素,是特异的 vacuolar-type H+ ATPase 抑制剂。
相关类别
靶点

H+ ATPase[1]

体外研究 低浓度(1nM)的巴弗洛霉素A1有效且特异性地抑制并杀死小儿B细胞急性淋巴细胞白血病细胞。它针对自噬途径的早期和晚期,线粒体并诱导不依赖caspase的细胞凋亡。巴弗洛霉素A1诱导Beclin 1与Bcl-2的结合,进一步抑制自噬并促进凋亡细胞死亡[1]。 BEL-7402肝细胞癌和HO-8910卵巢癌细胞系的生长受到阻滞,并且巴弗洛霉素A1抑制了转移潜能。透射电子显微镜和capsase-3和-9的测定表明,巴弗洛霉素A1诱导细胞凋亡[2]。巴弗洛霉素A1剂量依赖性地抑制多种培养细胞的生长,包括金仓鼠胚胎和NIH-3T3成纤维细胞,无论它们是否被转化,以及PC12和HeLa细胞。巴弗洛霉素A1抑制细胞生长的IC50范围为10至50 nM [3]。
体内研究 用低剂量巴弗洛霉素A1(0.1mg/kg)慢性治疗略微抑制肿瘤体积,但最终肿瘤体积与对照没有显着差异。然而,与对照组相比,高剂量巴弗洛霉素A1(1 mg/kg)的慢性治疗在21天后显着抑制肿瘤生长[4]。
细胞实验 使用0.05%胰蛋白酶收获细胞并悬浮于含有10%FCS的培养基中,并将200μL悬浮液加入96孔板的每个孔中。将细胞培养20小时以进行粘附。将巴弗洛霉素A1以200,400和800nM的终浓度加入孔中,一式三份。在24,48和72小时,向细胞中加入20μlWST-1。在37℃下孵育4小时后,读取平板以使用分光光度计[2]确定435nm处的光密度(OD)和675nm参比。
动物实验 小鼠:将携带肿瘤的小鼠随机分成三个实验组:低剂量巴弗洛霉素A1(0.1mg / kg每天)治疗组(n = 5),高剂量巴弗洛霉素A1(1mg / kg每天) - 治疗组(n = 5)和对照组(n = 5)。测量肿瘤大小并计算肿瘤体积倍增时间[2]。
参考文献

[1]. Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):345-56.

[2]. Lu X, et al. Bafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expression. Exp Ther Med. 2015 Nov;10(5):1829-1834.

[3]. Ohkuma S, et al. Inhibition of cell growth by bafilomycin A1, a selective inhibitor of vacuolar H(+)-ATPase. In Vitro Cell Dev Biol Anim. 1993 Nov;29A(11):862-6.

[4]. Ohta T, et al. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. J Pathol. 1998 Jul;185(3):324-30.

密度 1.1±0.1 g/cm3
沸点 770.1±60.0 °C at 760 mmHg
分子式 C35H58O9
分子量 622.830
闪点 232.2±26.4 °C
精确质量 622.408081
PSA 134.91000
LogP 3.88
蒸汽压 0.0±6.0 mmHg at 25°C
折射率 1.535
储存条件

2-8°C冷藏

分子结构

1、 摩尔折射率:171.94

2、 摩尔体积(m3/mol):552.3

3、 等张比容(90.2K):1438.8

4、 表面张力(dyne/cm):46.0

5、 极化率(10-24cm3):68.16

计算化学

1、 疏水参数计算参考值(XlogP):6

2、 氢键供体数量:4

3、 氢键受体数量:9

4、 可旋转化学键数量:7

5、 互变异构体数量:

6、 拓扑分子极性表面积(TPSA):135

7、 重原子数量:44

8、 表面电荷:0

9、 复杂度:1060

10、同位素原子数量:0

11、确定原子立构中心数量:12

12、不确定原子立构中心数量:0

13、确定化学键立构中心数量:4

14、不确定化学键立构中心数量:0

15、共价键单元数量:1

Name: Bafilomycin A1 Material Safety Data Sheet
Synonym:
CAS: 88899-55-2
Section 1 - Chemical Product MSDS Name:Bafilomycin A1 Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
88899-55-2 Bafilomycin A1 unlisted
Hazard Symbols: XI
Risk Phrases: 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use extinguishing media most appropriate for the surrounding fire.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a tightly closed container. Deep freeze (below -20C).

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 88899-55-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white to off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: soluble in ethanol
Specific Gravity/Density:
Molecular Formula:
Molecular Weight: 622.80

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Will not occur.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 88899-55-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Bafilomycin A1 - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 88899-55-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 88899-55-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 88899-55-2 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A
个人防护装备 dust mask type N95 (US);Eyeshields;Gloves
危害码 (欧洲) Xi: Irritant;
风险声明 (欧洲) R36/37/38
安全声明 (欧洲) 26-36
危险品运输编码 UN 3172
WGK德国 3
包装等级 III
危险类别 6.1(b)
上游产品  4

下游产品  0